Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.
During the past 5 years, better understanding of immunomodulatory and anti-angiogenesis properties of thalidomide has increased interest in the use of this agent for a wider variety of clinical applications. This article reviews the clinical evaluation of thalidomide for treatment or prevention of chronic graft-versus-host-disease.
Flowers
Mary E D
ME
Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., DS-290, PO Box 19024, Seattle, WA 98109-1024, USA. mflowers@fhcrc.org
Martin
Paul J
PJ
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D013792:Thalidomide / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide